Drugs / B2065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07371624 | Dec 2025 → Dec 2027 expected | ischemic stroke | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B2065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371624 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection” NCT07371624 ↗ |
| Route | Intravenous | “single intravenous infusion of B2065” NCT07371624 ↗ |